Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Health Canada finds Astrazeneca COVID-19 vaccines from Baltimore plant safe, of high quality

Published 2021-04-25, 06:02 p/m

April 25 (Reuters) - Canada's health department said on Sunday the 1.5 million doses of the Astrazeneca Plc AZN.L COVID-19 vaccine imported from Emergent BioSolutions' EBS.N Baltimore facility were safe and met quality specifications.

The U.S. Food and Drug Administration (FDA) had stopped AstraZeneca (NASDAQ:AZN) from using the facility earlier this month and halted production of Johnson & Johnson (NYSE:JNJ)'s JNJ.N vaccine at the plant as it began investigations into an error that led to millions of doses of J&J's vaccine being ruined last month. Health Canada said it reviewed test results of all vaccine lots that came into the country and found them to be safe.

J&J doses produced at the Baltimore, Maryland, site have not entered the country, the regulator said, adding that vaccines from the company anticipated to be imported next week were not made at that facility.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.